Pearl Therapeutics (Acquired by AstraZeneca)
Biopharmaceutical company that developed inhaled therapies for respiratory diseases including COPD. Acquired by AstraZeneca in 2013 for up to $1.15 billion.
Location
Redwood City, California, USA
Founded
2006
Investors
1
Categories
respiratory, therapeutics, copd, acquired
Notes
Pearl Therapeutics was a biopharmaceutical company focused on developing inhaled therapies for respiratory diseases, particularly chronic obstructive pulmonary disease (COPD). The company developed PT003, a combination therapy of formoterol and glycopyrrolate.
In 2013, AstraZeneca acquired Pearl Therapeutics for up to $1.15 billion ($560 million upfront plus milestones), gaining access to its respiratory pipeline and metered dose inhaler technology.
Team (at time of acquisition)
- Don Kellerman, Ph.D. - Chief Scientific Officer
- Leadership team from respiratory therapeutics backgrounds
Additional Research Findings
- Founded in 2006 in Redwood City, California
- Portfolio company of 5AM Ventures
- Acquired by AstraZeneca in 2013 for up to $1.15 billion
- Developed PT003 (now Bevespi Aerosphere) for COPD
- Pioneered metered dose inhaler (pMDI) technology
- Focus on combination therapies for respiratory diseases
- Products now part of AstraZeneca's respiratory portfolio
Sources
- AstraZeneca Acquisition Announcement
- Historical company information
Investors
| Name | Location | Type | Stages | Portfolio |
|---|---|---|---|---|
| 5AM Ventures | Menlo Park, USA | biotech-focused | seedseries-a+1 | 8 |